Background/aims: Probiotic effects on acute infectious diarrhea are strain(s) specific, and all formulations should be evaluated by clinical trials. We aimed to evaluate the effect of a synbiotic preparation on the duration of diarrhea in children compared to a zinc suspension.
Materials And Methods: We conducted a single-center, randomized, and controlled clinical trial in children with acute infectious diarrhea. The first group received a synbiotic preparation containing Lactobacillus casei, L. plantarum, L. rhamnosus, Bifidobacterium lactis and prebiotics; the second group received a zinc suspension (15 mg/day) for 5 days in addition to oral rehydration solution (ORS) and/or intravenous therapy. The third group received ORS and/or intravenous therapy (control group). The primary endpoint was the duration of diarrhea (in hours). The secondary endpoint was the percentage of children with diarrhea during each day of intervention.
Results: The duration of diarrhea was significantly reduced in the synbiotic and the zinc groups compared to the control group (91.0±28.9 hours vs. 114.3±30.9 hours, p<0.001; 86.4±30.8 hours vs. 114.3±30.9 hours, p<0.001, respectively). There was no significant difference in the duration of diarrhea between the synbiotic and zinc groups (p>0.05). At 72nd and 96th hours, the percentage of children with diarrhea was lower in the zinc group than in the synbiotic group (p<0.05 for both).
Conclusion: Our study showed that zinc or synbiotic supplementation reduced the duration of diarrhea, with better clinical outcomes at 72nd and 96th hours, and both can be used in children with acute diarrhea. To the best of our knowledge, this was the first study to make a comparison between zinc and synbiotics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5152/tjg.2016.16396 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of the complement system in Shiga toxin-associated hemolytic uremic syndrome.
Pediatr Nephrol
January 2025
Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Buenos Aires, Argentina.
Background: This research explores complement activation products involvement and risk and protective polymorphisms in the complement alternative pathway genes in Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) pathogenesis.
Methods: We analyzed the levels of complement activation products, C3a, C5a and soluble C5b-9 (sC5b-9) and plasma concentrations of Factor H (FH) and FH-related protein 1 (FHR-1) in 44 patients with STEC-HUS, 12 children with STEC-positive diarrhea (STEC-D), and 72 healthy controls (HC). STEC-HUS cases were classified as "severe" or "non-severe".
Disaccharidase Enzyme Deficiency in Adult Patients with Gas and Bloating.
Clin Transl Gastroenterol
January 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Wellstar Medical College of Georgia, Augusta University, Augusta, Georgia.
Introduction: Disaccharidases produced by the small intestinal brush border facilitate digestion of dietary carbohydrates. If deficient, they can cause carbohydrate malabsorption resulting in several abdominal symptoms. Our aim was to examine the prevalence of disaccharidase deficiency and correlate this with abdominal symptoms in adult patients with chronic abdominal symptoms.
View Article and Find Full Text PDFTrastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
J Clin Oncol
January 2025
Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Purpose: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC.
Methods: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.
Third generation vs first generation EGFR-TKIs in the first line treatment for EGFR-mutated locally advanced or metastatic non-small cell lung cancer: a meta-analysis based on randomized controlled trials.
J Cancer
January 2025
Department of Respiratory and Critical Care Medicine, The Second People's Hospital of Jingdezhen, Jingdezhen, China.
The prevailing belief is that third-generation tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) (TGET) outperform first-generation EGFR-TKIs (FGET) in managing advanced-stage EGFR-mutated non-small cell lung cancer (NSCLC). However, this standpoint lacks substantiation in evidence-based medicine. Therefore, this meta-analysis was conducted to compare the efficacy and adverse effects (AEs) of these two categories.
View Article and Find Full Text PDFImpact of Clindamycin on the Oral-Gut Axis: Gastrointestinal Side Effects and Clostridium difficile Infection in 45 Patients.
Cureus
December 2024
Private Practice and Research, American Dental Association, Penfield, USA.
Introduction The use of antibiotics such as oral clindamycin has been effective in treating bacterial infections. However, this medication often comes with significant side effects, particularly those affecting the gastrointestinal (GI) system. This study aims to evaluate the impact of different doses of clindamycin on GI health, specifically examining side effects like stomach upset, diarrhea duration, stomach pain, and recovery time.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!